Clinical features and treatment responses in 40 male patients with VEXAS syndrome
HMA treatment shows promise for VEXAS syndrome patients
This retrospective multicenter study of 40 male patients with VEXAS syndrome evaluated clinical features and various treatment responses. Re…
New data on VEXAS syndrome suggests that hypomethylating agents may help improve clinical and biological responses in men.
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value.
Frail Leukemia Patients See Better Results With New Blood Monitoring
This single-center retrospective analysis evaluated long-course venetoclax combined with hypomethylating agents in unfit AML patients. Resul…
A new look at blood tests shows how well frail leukemia patients respond to standard treatment.
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS. The analysis pooled …
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…